Revolution Medicines, Inc. provided earnings guidance for the full year 2022. For the period, the company projected GAAP net loss to be between $260 million and $280 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.77 USD | +0.28% | +0.96% | +38.67% |
May. 09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
May. 08 | Revolution Medicines Q1 Net Loss Narrows | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.67% | 6.54B | |
+64.23% | 55.07B | |
-2.31% | 41.79B | |
+44.36% | 40.22B | |
-8.29% | 28.17B | |
+11.97% | 26.28B | |
-21.16% | 18.93B | |
+7.54% | 13.03B | |
+27.17% | 12.26B | |
+25.72% | 12.21B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2022